Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi !

P27KIP1 in acute myeloid leukemia (CROSBI ID 579700)

Prilog sa skupa u časopisu | sažetak izlaganja sa skupa | međunarodna recenzija

Sučić, Mirna ; Hodak, Nataša ; Marković-Glamočak, Mirjana ; Ries, Sunčica ; Gjadrov Kuveždić, Koraljka ; Labar, Boris P27KIP1 in acute myeloid leukemia // Haematologica / Cazzola, Mario (ur.). 2010. str. 506-506

Podaci o odgovornosti

Sučić, Mirna ; Hodak, Nataša ; Marković-Glamočak, Mirjana ; Ries, Sunčica ; Gjadrov Kuveždić, Koraljka ; Labar, Boris

engleski

P27KIP1 in acute myeloid leukemia

Acute leukemia (AL) is clonal proliferation of immature leukemia cells in bone marrow (BM, peripheral blood and other tissue. Uncontrolled clonal proliferation caused by malignant transformation of cells is a result of many alterations of cell functions, involved in cell proliferation, differentiation and apoptosis. Malignant transformation of leukemic cells is also associated with altered activity of cyclin dependent kinases (CDKs) and cyclin-dependent kinase inhibitors CKIs. CDKs form periodically complexes with cyclins and induce cell cycle progression from G1 to S phase. One of CKIs is p27Kip1 member of KIP (kinase inhibitor proteins) family. Aim of this study was to analyze p27Kip1 immunocytochemical expression of BM hematopoietic cells (HCs) in AML patients before cytostatic therapy and in 11 control group of patients. Methods: microscopic analysis of p27Kip1 positive HCs was done after immunocytochemical APAAP staining of BM smears. Analyses were done in 14 AML patients and 11 patients of control group (not suffering of hematological malignant disease). BM analysis in control group was done in course of standard diagnostics and from all patients in both groups informed consent was obtained. Results: median (8%) and upper limit (45%) of percentages of p27Kip1 positive HCs in control group were higher than same parameters in leukemic cells (median: 2, 3% ; upper limit 18%). Moreover, percentages of p27Kip1 positive HCs in control group were significantly higher (p<0.001) than in AML patients. In 2 out of 14 AML patients was found higher percentage of p27Kip1 positive HCs (5%, 18%). Conclusions: Results of this study point to lower expression pf p27 in AML leukemic cells in comparison to normal hematopoietic cells in control group. Observations are in relation with known p27Kip1 function acting as CKIs of cell cycle progression and with other studies findings implicating variability of p27Kip1 immunoexpression in leukemic cells.

acute leukemia; P27KIP1

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o prilogu

506-506.

2010.

nije evidentirano

objavljeno

Podaci o matičnoj publikaciji

Haematologica

Cazzola, Mario

Pavia: Ferrata-Starti Foundation

0390-6078

Podaci o skupu

15th Congress of the European Hematology Association

ostalo

10.06.2010-13.06.2010

Barcelona, Španjolska

Povezanost rada

Kliničke medicinske znanosti, Farmacija

Indeksiranost